The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A comprehensive review of over a decade of clinical research

CNS Drugs

Volumn 29, Issue 2, 2015, Pages 131-151

  Savill, Nicola C ^a   Buitelaar, Jan K ^b,c   Anand, Ernie ^a   Day, Kathleen Ann ^a   Treuer, Tamás ^a   Upadhyaya, Himanshu P ^a   Coghill, David ^d  

^a ELI LILLY AND COMPANY   (United States)

^b RADBOUD UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADOLESCENT; ADOLESCENT DISEASE; ANXIETY DISORDER; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DYSLEXIA; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; INTELLIGENCE QUOTIENT; MENTAL DEFICIENCY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TIC; TREATMENT RESPONSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMORBIDITY; COMPLICATION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COMORBIDITY; HUMANS; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925496852     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0224-9     Document Type: Review

References (170)

1. Young ME, Galvan T, Reidy BL, et al. Family functioning deficits in bipolar disorder and ADHD in youth. J Affect Disord. 2013;150(3):1096-102.
2. Langley K, Fowler T, Ford T, et al. Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry. 2010;196(3):235-40.
3. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29(4):546-57.
4. Babinski DE, Pelham WE Jr, Molina BS, et al. Late adolescent and young adult outcomes of girls diagnosed with ADHD in childhood: an exploratory investigation. J Atten Disord. 2011;15(3):204-14.
5. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry. 2000;39(11):1424-31.
6. Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. Med Gen Med. 2006;8(3):12.
7. Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. Long-term criminal outcome of children with attention deficit hyperactivity disorder. Crim Behav Ment Health. 2013;23(2):86-98.
8. Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990-1002.
9. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-13.
10. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490-9.
11. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-8.
12. Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434-42.
13. Kornfield R, Watson S, Higashi AS, et al. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr Serv. 2013;64(4):339-46.
14. Cardo E, Porsdal V, Quail D, et al. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23(4):252-61.
15. Banaschewski T, Roessner V, Dittmann RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):102-16.
16. Upadhyaya HP, Desaiah D, Schuh KJ, et al. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology. 2013;226(2):189-200.
17. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140-7.
18. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
19. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896-901.
20. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(7):647-55.
21. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-8.
22. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol. 2014;28(3):204-11.
23. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174-87.
24. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):e145-57.
25. Agster KL, Bates AT, Cain RE, et al. The role of cortical norepinephrine in the development of executive function. Neuropsychopharmacology. 2011;36:S83.
26. Gehlert DR, Schober DA, Hemrick-Luecke SK, et al. Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int. 1995;26(1):47-52.
27. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-58.
28. Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982;222(1):61-5.
29. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52(12):1023-9.
30. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
31. Volz TJ, Farnsworth SJ, Rowley SD, et al. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. J Pharmacol Exp Ther. 2008;327(1):161-7.
32. Calipari ES, Ferris MJ, Salahpour A, et al. Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun. 2013;4:2720.
33. Hutson PH, Pennick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014;87C:41-50.
34. Fan X, Hess EJ. D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD. Neurobiol Dis. 2007;26(1):201-11.
35. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284-95.
36. Molina BS, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112(3):497-507.
37. Upadhyaya HP, Rose K, Wang W, et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol. 2005;15(5):799-809.
38. Galéra C, Melchior M, Chastang JF, et al. Childhood and adolescent hyperactivity-inattention symptoms and academic achievement 8 years later: the GAZEL Youth study. Psychol Med. 2009;39(11):1895-906.
39. Rucklidge JJ. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2010;33(2):357-73.
40. Tanaka Y, Rohde LA, Jin L, et al. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions. J Child Adolesc Psychopharmacol. 2013;23(4):262-70.
41. Rommelse NN, Geurts HM, Franke B, et al. A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes. Neurosci Biobehav Rev. 2011;35(6):1363-96.
42. Rommelse NN, Franke B, Geurts HM, et al. Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry. 2010;19(3):281-95.
43. Udvardi PT, Föhr KJ, Henes C, et al. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain - an in vivo study. Drug Des Devel Ther. 2013;7:1433-46.
44. STRATTERA®. Clinical study results. Eli Lilly and Co. http://www.lillytrials.com/results/Strattera.pdf. Accessed 5 Dec 2014.
45. STRATTERA®. Summary of product characteristics. Eli Lilly and Co. http://www.medicines.org.uk/emc/medicine/14482. Accessed 27 Nov 2014.
46. STRATTERA®. Full prescribing information. Eli Lilly and Co. http://www.pi.lilly.com/us/strattera-pi.pdf. Accessed 27 Nov 2014.
47. Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry. 2010;49(6):573-82.
48. Schulz KP, Fan J, Bédard AC, et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2012;69(9):952-61.
49. Ramoz N, Boni C, Downing AM, et al. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009;34(9):2135-42.
50. Yang L, Qian Q, Liu L, et al. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm. 2013;120(7):1127-33.
51. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46(2):242-51.
52. Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord. 2009;1(2):201-10.
53. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):511-8.
54. Dickson RA, Maki E, Gibbins C, et al. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health. 2011;5(14).
55. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006;149(1):112-9.
56. Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61(5):694-9.
57. Perwien AR, Faries DE, Kratochvil CJ, et al. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr. 2004;25(4):264-71.
58. Urion DK. Atomoxetine "treatment failures" usually respond to dosing changes. Ann Neurol. 2012;72:S186-7.
59. Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr. 2009;48(7):723-33.
60. Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol. 2011;21(2):97-110.
61. Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11(2):167-70.
62. Cho S, Lee SI, Yoo H, et al. A randomized, open-label assessment of response to various doses of atomoxetine in Korean pediatric outpatients with attention-deficit/hyperactivity disorder. Psychiatry Investig. 2011;8(2):141-8.
63. Takahashi M, Takita Y, Yamazaki K, et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(4):341-50.
64. Wietecha LA, Williams DW, Herbert M, et al. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):719-30.
65. Newcorn JH, Michelson D, Kratochvil CJ, et al. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics. 2006;118(6):e1701-6.
66. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11(3):251-65.
67. Kratochvil CJ, Michelson D, Newcorn JH, et al. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1128-37.
68. Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27(12):1081-92.
69. Martenyi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry. 2010;19(1):57-66.
70. Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(6):e75.
71. Dittmann RW, Wehmeier PM, Schacht A, et al. Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians. Child Adolesc Psychiatry Ment Health. 2009;3(1):21.
72. Buitelaar JK, Danckaerts M, Gillberg C, et al. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2004;13(4):249-57.
73. Tamayo JM, Pumariega A, Rothe EM, et al. Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18(1):44-53.
74. Durell TM, Pumariega AJ, Rothe EM, et al. Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2009;21(1):26-37.
75. Block SL, Williams D, Donnelly CL, et al. Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients. Clin Pediatr. 2010;49(8):768-76.
76. Montoya A, Quail D, Anand E, et al. Prognostic factors of improvement in health related quality of life in children and adolescents with attention deficit/hyperactivity disorder, after atomoxetine treatment. Eur Psychiatry. 2012;27(Suppl 1):1.
77. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(7):896-904.
78. Hazell P, Zhang S, Wolańczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2006;15(2):105-10.
79. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(8):919-27.
80. Wehmeier PM, Dittmann RW, Schacht A, et al. Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health. 2009;3(1):5.
81. Wehmeier PM, Schacht A, Ulberstad F, et al. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology. J Clin Psychopharmacol. 2012;32(5):653-60.
82. Wilens TE, Hammerness P, Utzinger L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009;19(5):485-92.
83. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1):275-89.
84. Faraone SV, Wigal SB, Hodgkins P. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Atten Disord. 2007;11(1):74-82.
85. Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P. Systematic review and network meta-analysis of treatments used for attention deficit hyperactivity disorder (ADHD). Value Health. 2012;15(7):A334.
86. Sikirica V, Findling RL, Signorovitch J, et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs. 2013;27(11):943-53.
87. Bastiaens L. Effectiveness and tolerability of atomoxetine in a real-world ADHD population: nonrandomized comparison with stimulants. Psychiatry. 2007;4(12):44-8.
88. Whalen CK, Henker B, Ishikawa SS, et al. Atomoxetine versus stimulants in the community treatment of children with ADHD: an electronic diary study. J Atten Disord. 2010;13(4):391-400.
89. Fuentes J, Danckaerts M, Cardo E, et al. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2013;33(6):766-74.
90. Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord. 2011;15(8):674-83.
91. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176.
92. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-84.
93. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29(12):1573-85.
94. Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23(2):379-94.
95. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust NZ J Psychiatry. 2007;41(3):222-30.
96. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721-30.
97. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005;22(5):498-512.
98. Yildiz O, Sismanlar SG, Memik NC, et al. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry Hum Dev. 2011;42(3):257-69.
99. Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc. 2005;97(10):11S-6S.
100. Mazzone L, Postorino V, Reale L, et al. Self-esteem evaluation in children and adolescents suffering from ADHD. Clin Pract Epidemiol Ment Health. 2013;9:96-102.
101. Biederman J, Spencer TJ, Newcorn JH, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology. 2007;190(1):31-41.
102. Dell'Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009;19(11):822-34.
103. Brown RT, Perwien A, Faries DE, et al. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr. 2006;45(9):819-27.
104. Cheng JY, Chen RY, Ko JSN, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents - meta-analysis and meta-regression analysis. Psychopharmacology. 2007;194(2):197-209.
105. Dittmann RW, Wehmeier PM, Schacht A, et al. Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings. Atten Defic Hyperact Disord. 2009;1(2):187-200.
106. Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):253-63.
107. Escobar R, Schacht A, Wehmeier PM, Wagner T. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials. J Clin Psychopharmacol. 2010;30(2):145-51.
108. Donnelly C, Faries D, Swensen A, et al. The effect of atomoxetine on the social and family functioning of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Eur Neuropsychopharmacol. 2002;12(Suppl 3):S437.
109. Maziade M, Rouleau N, Lee B, et al. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19(6):709-18.
110. Van Der Kolk A, Bouwmans C, Schawo S, et al. The quality of life of children with ADHD and their parents: results of EQ-5D and Kidscreen-10. Value Health. 2011;14(7):A294-5.
111. Perwien AR, Kratochvil CJ, Faries DE, et al. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol. 2006;16(6):713-24.
112. Matza LS, Rentz AM, Secnik K, et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004;25(3):166-74.
113. Bastiaens L. Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants. Psychiatr Q. 2011;82(4):303-8.
114. Buitelaar JK, Wilens TE, Zhang S, et al. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry. 2009;50(3):335-42.
115. Waxmonsky JG, Waschbusch DA, Pelham WE, et al. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(11):1535-51.
116. Wehmeier PM, Dittmann RW, Schacht A, et al. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study. J Child Adolesc Psychopharmacol. 2007;17(6):813-30.
117. Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. Qual Life Res. 2011;20(5):691-702.
118. Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):240-8.
119. Dumitru I, Salan A. Treating children with epilepsy and comorbid attention-deficit/hyperactivity disorder (ADHD). Eur J Neurol. 2012;19:208.
120. Shang CY, Gau SS. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(5):353-63.
121. Svanborg P, Thernlund G, Gustafsson PA, et al. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18(12):725-35.
122. Wehmeier PM, Schacht A, Dittmann RW, Banaschewski T. Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord. 2010;2(2):73-85.
123. Wehmeier PM, Schacht A, Escobar R, et al. Health-related quality of life in ADHD: a pooled analysis of gender differences in five atomoxetine trials. Atten Defic Hyperact Disord. 2012;4(1):25-35.
124. Wehmeier PM, Schacht A, Escobar R, et al. Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and attention deficit/hyperactivity disorder core symptoms: meta-analysis of five atomoxetine trials. Child Adolesc Psychiatry Ment Health. 2010;4:30.
125. Saylor K, Williams DW, Schuh KJ, et al. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. Curr Med Res Opin. 2010;26(9):2087-95.
126. Quintana H, Cherlin EA, Duesenberg DA, et al. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder - a preliminary tolerability and efficacy study. Clin Ther. 2007;29(6):1168-77.
127. Heiligenstein JH, Dunn DW, Busner J, et al. Efficacy of tomoxetine versus placebo in school-age children with ADHD who failed psychostimulant treatment. 154th Annual Meeting of the American Psychiatric Association. 2001 5-10 May; New Orleans, LA.
128. Hammerness P, Doyle R, Kotarski M, et al. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study. Eur Child Adolesc Psychiatry. 2009;18(8):493-8.
129. Bakken RJ, Paczkowski M, Kramer HP, et al. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Curr Med Res Opin. 2008;24(2):449-60.
130. Niederkirchner K, Slawik L, Wermelskirchen D, et al. Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Rev Neurother. 2011;11(4):499-508.
131. Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009;25(11):2745-54.
132. Mendez L, Singh P, Harrison G, et al. Academic outcomes in Asian children aged 8-11 years with attention-deficit/hyperactivity disorder treated with atomoxetine hydrochloride. Int J Psychiatry Clin Pract. 2011;15(2):145-56.
133. Wehmeier PM, Dittmann RW, Banaschewski T, Schacht A. Does stimulant pretreatment modify atomoxetine effects on core symptoms of ADHD in children assessed by quantitative measurement technology? J Atten Disord. 2014;18(2):105-16.
134. Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18(4):240-9.
135. Wilens TE, Kratochvil C, Newcorn JH, Gao H. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry. 2006;45(2):149-57.
136. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
137. Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407-20.
138. Zeiner P, Gjevik E, Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr. 2011;100(9):1258-61.
139. Biederman J, Wigal SB, Spencer TJ, et al. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther. 2006;28(2):280-93.
140. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008;11(4):470-81.
141. Gilbert DL, Zhang J, Lipps TD, et al. Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement. Clin Neurophysiol. 2007;118(8):1835-41.
142. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941-9.
143. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48(9):884-93.
144. Chang K, Nayar D, Howe M, Rana M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009;19(5):547-51.
145. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119-27.
146. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-24.
147. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics. 2008;121(2):e314-20.
148. Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004;8(2):45-52.
149. Ercan ES, Akyol Ardic U, Kabukcu Basay B, et al. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review. Atten Defic Hyperact Disord. 2013;5(4):377-85.
150. Wehmeier PM, Kipp L, Banaschewski T, et al. Does comorbid disruptive behavior modify the effects of atomoxetine on ADHD symptoms as measured by a continuous performance test and a motion tracking device? J Atten Disord. doi: 10.1177/1087054712456739 (Epub 2012 Aug 28).
151. Waxmonsky JG, Waschbusch DA, Akinnusi O, Pelham WE. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(1):21-32.
152. van Wyk GW, Hazell PL, Kohn MR, et al. How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis. J Atten Disord. 2012;16(4):314-24.
153. Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 2):130-7.
154. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Washington, DC: American Psychiatric Association; 2013.
155. Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(7):733-41.
156. Harfterkamp M, Buitelaar JK, Minderaa RB, et al. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol. 2013;23(3):194-9.
157. Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. J Atten Disord. 2011;15(8):684-9.
158. Posey DJ, Wiegand RE, Wilkerson J, et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):599-610.
159. Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolescent Psychopharmacol. 2006;16(5):611-9.
160. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-205.
161. Mazzone L, Reale L, Mannino V, et al. Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs. 2011;25(6):503-9.
162. Fernández-Jaén A, Fernández-Mayoralas DM, Calleja Pérez B, et al. Atomoxetine for attention deficit hyperactivity disorder in mental retardation. Pediatr Neurol. 2010;43(5):341-7.
163. Shaywitz SE, Shaywitz BA, Wietecha LA, et al. Effects of atomoxetine on reading abilities in children with dyslexia and children with attention deficit/hyperactivity disorder and comorbid dyslexia. Ann Neurol. 2012;72:S204.
164. Sumner CR, Gathercole S, Greenbaum M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia. Child Adolesc Psychiatry Ment Health. 2009;3:40.
165. Gau SSF, Huang YS, Soong WT, et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine hydrochloride in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(4):447-60.
166. Biederman J, Gao H, Rogers AK, Spencer TJ. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry. 2006;60(10):1106-10.
167. Bohnstedt BN, Kronenberger WG, Dunn DW, et al. Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants. J Atten Disord. 2005;8(4):153-9.
168. Vakula N, Vasyanina Y, Gorbunova Z, et al. Efficacy of Strattera in children and adolescents with attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2010;40(9):1034-7.
169. Sumner CR, Haynes VS, Teicher MH, Newcorn JH. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder? Postgrad Med. 2010;122(5):52-61.
170. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health. 2008;2(1):25.